IPHA · NASDAQ · Biotechnology

Innate Pharma (ADR) (IPHA)

Develops innate-immunity-based antibody therapies for cancer alongside AstraZeneca and Sanofi collaborations.

$1.76
vs last close−0.04 (−2.22%)